Written by: Danny Olszta, PharmD, BCOP Jolliet Oncology Hematology Associates
Download Here

For patients with Non‐Small Cell Lung Cancer (NSCLC) that have sensitizing epidermal growth factor receptor (EGFR) mutations (most commonly exon 19 deletions or exon 21 L858R mutations) appropriate for first‐line treatment with an EGFR inhibitor, osimertinib (Tagrisso) has a clear progression free survival (PFS) benefit compared to chemotherapy and has been recently recommended as a preferred first line agent according to the NCCN guidelines. If another EGFR inhibitor is being prescribed for a patient with a sensitizing EGFR mutation, the pharmacist will contact the Physician to determine why the current therapy was chosen.

Continue reading EGFR Inhibitors

Read More

Written by Danny Olszta, PharmD, BCOP Jolliet Oncology Hematology Associates
Download Here

Chronic Lymphocytic Leukemia (CLL) diagnosis with the chromosomal abnormality of 17p Deletion is associated with a poor prognosis. The 17p deletion is found 3‐10% of the time at diagnosis, but 30‐ 50% at relapse. Testing rates at diagnosis and especially relapse are low. Venetoclax is approved in patients who have relapsed after one therapy and have the 17p deletion. Continue reading CLL and Del17P

Read More

Written By: Todd Murphree, PharmD Clearview Cancer Institute
Download Here

Jakafi (ruxolitinib) is a selective Jak2 inhibitor used for the treatment of myelofibrosis (MF). This PQI will review the close monitoring of platelets required to ensure appropriate dose and avoid severe thrombocytopenia due to the therapy.
Continue reading Managing Myelofibrosis Patients

Read More